AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu showed positive results across multiple HER2-expressing advanced solid tumors in heavily pre-treated patients.
Genome engineering company Replay and The University of Texas’ MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.
Merck and New Jersey-based Nectin Therapeutics announced a research collaboration agreement Tuesday to study the safety and efficacy of Nectin’s investigational antibody NTX1088 in locally advanced and metastatic solid tumors.
AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company for $320 million.
AstraZeneca dosed the first patient in a Phase II portion of an ongoing trial assessing a PD-1/TIGIT bispecific antibody, triggering a $7.5 million milestone payment to partner, Compugen.
Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
Seagen and LAVA Therapeutics inked a licensing deal for LAVA’s Gammabody platform for solid tumors, which can potentially exceed $700 million.